Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis has the "secret sauce" for developing drugs through to commercialisation

Pharmaxis Ltd (ASX:PXS) non-executive director Dr Kathleen Metters explains what attracted her to the board of the pharmaceutical research company less than a year ago, following a long and illustrious career in big pharma.

"This is an incredibly innovative research group. They have managed to move into the clinic - and not just into the clinic but into pre-clinical development - compounds for particular, what we call, therapeutic targets to test new mechanisms that has never been done in the industry before," says Metters.

"I realised they just had all the qualities to do it again and again and again. They are really rigorous scientists... they know every step of the business; this is a small company but it goes from research through to commercialisation, so they have really exquisite line of sight on what they need to do to bring forward new therapies," Metters continues.

Pharmaxis is in talks for a partnership deal on its LOXL2 anti‐fibrotic program, with hopes of announcing a partner in the second half of this year.

 
Meet High Peak Royalties Ltd, Yandal Resources, MMJ PhytoTech Ltd, Minotaur Exploration Ltd and Hydroponics Company Ltd at our event, Sydney , 22 October 2018. Register here »
View full PXS profile View Profile

Pharmaxis Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use